Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Neoplasms 1Myeloproliferative Disorders 1Glioma 1Cholangiocarcinoma 1

Interventions

Gemcitabine 15Cisplatin 13durvalumab 12pembrolizumab 10Oxaliplatin 8Magnetic Resonance Spectroscopy 8Biopsy 7Specimen Handling 6Leucovorin 6Fluorouracil 5Paclitaxel 4Folfox protocol 4futibatinib 3Taxes 3Radiation 3Nivolumab 3Irinotecan 3Immunoglobulin G 3Disulfides 3tislelizumab 2pemigatinib 2olaparib 2lenvatinib 2fludarabine 2dehydroftorafur 2Radiation Dose Hypofractionation 2Platinum 2Liver Transplantation 2Fluorodeoxyglucose F18 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × olutasidenib × 90 days × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡